Skip to main content
Clinical Trials/NCT06619795
NCT06619795TerminatedNot Applicable

Combined Effect of tDCS and Motor or Cognitive Activity in Patients With Alzheimer's Disease: A Proof-of-Concept Pilot Study

Universita di Verona2 sites in 1 country23 target enrollmentStarted: June 1, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Enrollment
23
Locations
2
Primary Endpoint
Mini Mental State Examination (MMSE)

Study Overview

Brief Summary

The goal of this clinical trial is to evaluate the effectiveness of combining tDCS with motor or cognitive activities on cognitive functions in patients with AD. Second aim is to investigate if tDCS has a different impact if it is combined with motor or cognitive activities.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Mini Mental State Examination (MMSE) major or equal to 15;
  • good level of compliance;
  • acetylcholinesterase inhibitor treatment (e.g., donepezil, rivastigmine);
  • no modifications of medication during the last four months.

Exclusion Criteria

  • behavioral disorders (e.g., aggressiveness);
  • alcohol abuse;
  • orthopedic pathology with risk of falls to the ground;
  • respiratory pathology;
  • severe auditory or visual deficits uncorrected;
  • history of epileptic fits;
  • anti-epileptic medication;
  • metallic body implants; pacemaker;
  • psychiatric, neurologic, systemic or metabolic disorders.

Outcomes

Primary Outcomes

Mini Mental State Examination (MMSE)

Time Frame: From enrollment to the end of treatment at two weeks

(Range: 0-30; higher score=best performance).

Secondary Outcomes

  • Picture Recognition (PR)(From enrollment to the end of treatment at two weeks)
  • Digit Span Test- Forward (DSF)(From enrollment to the end of treatment at two weeks)
  • Digit Span Test- Backward (DSB)(From enrollment to the end of treatment at two weeks)
  • Phonemic Fluency Test (PFT)(From enrollment to the end of treatment at two weeks)
  • Visual Search Test (VST)(From enrollment to the end of treatment at two weeks)
  • Sustained Attention to Response Test (SART)(From enrollment to the end of treatment at two weeks)
  • Neuropsychiatric Inventory (NPI)(From enrollment to the end of treatment at two weeks)

Investigators

Sponsor
Universita di Verona
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Valentina Varalta

Doctor

Universita di Verona

Study Sites (2)

Loading locations...

Similar Trials